JP2020524490A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524490A5 JP2020524490A5 JP2019567283A JP2019567283A JP2020524490A5 JP 2020524490 A5 JP2020524490 A5 JP 2020524490A5 JP 2019567283 A JP2019567283 A JP 2019567283A JP 2019567283 A JP2019567283 A JP 2019567283A JP 2020524490 A5 JP2020524490 A5 JP 2020524490A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- item
- coli
- promoter
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000588724 Escherichia coli Species 0.000 claims description 88
- 108090000623 proteins and genes Proteins 0.000 claims description 87
- 241000701959 Escherichia virus Lambda Species 0.000 claims description 28
- 230000000813 microbial effect Effects 0.000 claims description 24
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 12
- 230000006696 biosynthetic metabolic pathway Effects 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 8
- 102000004877 Insulin Human genes 0.000 claims description 8
- 108090001061 Insulin Proteins 0.000 claims description 8
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 claims description 8
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 8
- 229940125396 insulin Drugs 0.000 claims description 8
- 108010050904 Interferons Proteins 0.000 claims description 6
- 102000014150 Interferons Human genes 0.000 claims description 6
- 101150118992 dxr gene Proteins 0.000 claims description 6
- 229940079322 interferon Drugs 0.000 claims description 6
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 5
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 5
- 239000000854 Human Growth Hormone Substances 0.000 claims description 5
- 108010057186 Insulin Glargine Proteins 0.000 claims description 5
- 108010005714 Interferon beta-1b Proteins 0.000 claims description 5
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 5
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- 108010010648 interferon alfacon-1 Proteins 0.000 claims description 5
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 5
- 229960004999 lycopene Drugs 0.000 claims description 5
- 235000012661 lycopene Nutrition 0.000 claims description 5
- 239000001751 lycopene Substances 0.000 claims description 5
- 230000037361 pathway Effects 0.000 claims description 5
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 5
- 102000055006 Calcitonin Human genes 0.000 claims description 4
- 108060001064 Calcitonin Proteins 0.000 claims description 4
- 102000051325 Glucagon Human genes 0.000 claims description 4
- 108060003199 Glucagon Proteins 0.000 claims description 4
- 102000018997 Growth Hormone Human genes 0.000 claims description 4
- 108010051696 Growth Hormone Proteins 0.000 claims description 4
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 claims description 4
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 claims description 4
- 108010065920 Insulin Lispro Proteins 0.000 claims description 4
- 102100040018 Interferon alpha-2 Human genes 0.000 claims description 4
- 108010047761 Interferon-alpha Proteins 0.000 claims description 4
- 102000006992 Interferon-alpha Human genes 0.000 claims description 4
- 108010079944 Interferon-alpha2b Proteins 0.000 claims description 4
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 4
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 4
- 101150047711 acs gene Proteins 0.000 claims description 4
- 229960004015 calcitonin Drugs 0.000 claims description 4
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims description 4
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 4
- 229960004666 glucagon Drugs 0.000 claims description 4
- 239000000122 growth hormone Substances 0.000 claims description 4
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 claims description 4
- 102000058004 human PTH Human genes 0.000 claims description 4
- BYMJQPSBSTWSGH-UHFFFAOYSA-N humarin Natural products OCC1OC(OCC2OC(OC(=O)c3cc(O)c(O)c(O)c3)C(O)C(O)C2O)C(O)C(O)C1OC(=O)c4cc(O)c(O)c(O)c4 BYMJQPSBSTWSGH-UHFFFAOYSA-N 0.000 claims description 4
- 229940090438 infergen Drugs 0.000 claims description 4
- 229960002068 insulin lispro Drugs 0.000 claims description 4
- 229940065638 intron a Drugs 0.000 claims description 4
- 229940060975 lantus Drugs 0.000 claims description 4
- 229940076783 lucentis Drugs 0.000 claims description 4
- 239000000199 parathyroid hormone Substances 0.000 claims description 4
- 229960001319 parathyroid hormone Drugs 0.000 claims description 4
- 108010068072 salmon calcitonin Proteins 0.000 claims description 4
- 229960004532 somatropin Drugs 0.000 claims description 4
- 229960003102 tasonermin Drugs 0.000 claims description 4
- 108700026220 vif Genes Proteins 0.000 claims description 4
- PVPAMMQRQRLZBS-UHFFFAOYSA-N 1-hydroxy-7,9-dihydro-3h-purine-2,6,8-trione Chemical compound O=C1N(O)C(=O)NC2=C1NC(=O)N2 PVPAMMQRQRLZBS-UHFFFAOYSA-N 0.000 claims description 3
- 101100056285 Escherichia coli (strain K12) ariR gene Proteins 0.000 claims description 3
- 101100126274 Escherichia coli (strain K12) iraM gene Proteins 0.000 claims description 3
- 108010092217 Long-Acting Insulin Proteins 0.000 claims description 3
- 102000016261 Long-Acting Insulin Human genes 0.000 claims description 3
- 229940100066 Long-acting insulin Drugs 0.000 claims description 3
- 101150050866 argD gene Proteins 0.000 claims description 3
- 101150107204 asd gene Proteins 0.000 claims description 3
- 101150034124 ask gene Proteins 0.000 claims description 3
- 101150081158 crtB gene Proteins 0.000 claims description 3
- 101150000046 crtE gene Proteins 0.000 claims description 3
- 101150085103 crtY gene Proteins 0.000 claims description 3
- 101150011371 dapA gene Proteins 0.000 claims description 3
- 101150073654 dapB gene Proteins 0.000 claims description 3
- 101150064923 dapD gene Proteins 0.000 claims description 3
- 101150000582 dapE gene Proteins 0.000 claims description 3
- 101150062988 dapF gene Proteins 0.000 claims description 3
- 101150057904 ddh gene Proteins 0.000 claims description 3
- 101150056470 dxs gene Proteins 0.000 claims description 3
- 101150089768 elbB gene Proteins 0.000 claims description 3
- 101150057497 fbp gene Proteins 0.000 claims description 3
- 101150118781 icd gene Proteins 0.000 claims description 3
- 101150075592 idi gene Proteins 0.000 claims description 3
- 101150064873 ispA gene Proteins 0.000 claims description 3
- 101150000769 ispB gene Proteins 0.000 claims description 3
- 101150014059 ispD gene Proteins 0.000 claims description 3
- 101150068863 ispE gene Proteins 0.000 claims description 3
- 101150018742 ispF gene Proteins 0.000 claims description 3
- 101150081094 ispG gene Proteins 0.000 claims description 3
- 101150017044 ispH gene Proteins 0.000 claims description 3
- 101150033534 lysA gene Proteins 0.000 claims description 3
- 101150044424 lysE gene Proteins 0.000 claims description 3
- 101150088738 pckA gene Proteins 0.000 claims description 3
- 101150067708 pckG gene Proteins 0.000 claims description 3
- 101150053253 pgi gene Proteins 0.000 claims description 3
- 101150023641 ppc gene Proteins 0.000 claims description 3
- 101150096049 pyc gene Proteins 0.000 claims description 3
- 101150106048 ymgA gene Proteins 0.000 claims description 3
- 101150078419 zwf gene Proteins 0.000 claims description 3
- 101150099894 GDHA gene Proteins 0.000 claims description 2
- 229960004859 glucarpidase Drugs 0.000 claims description 2
- 108010049491 glucarpidase Proteins 0.000 claims description 2
- 101150013067 appY gene Proteins 0.000 claims 1
- 229960000074 biopharmaceutical Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229940065770 humatrope Drugs 0.000 claims 1
- 229960003358 interferon alfacon-1 Drugs 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 91
- 238000004519 manufacturing process Methods 0.000 description 80
- 230000007614 genetic variation Effects 0.000 description 73
- 108090000790 Enzymes Proteins 0.000 description 22
- 102000004190 Enzymes Human genes 0.000 description 22
- 238000013461 design Methods 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 17
- 238000000354 decomposition reaction Methods 0.000 description 16
- 230000015556 catabolic process Effects 0.000 description 14
- 238000006731 degradation reaction Methods 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 13
- 230000004568 DNA-binding Effects 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 10
- 239000002207 metabolite Substances 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 6
- 102000054765 polymorphisms of proteins Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000446 fuel Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 150000003384 small molecules Chemical group 0.000 description 5
- 108010029961 Filgrastim Proteins 0.000 description 4
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 4
- 229960004177 filgrastim Drugs 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 230000001851 biosynthetic effect Effects 0.000 description 3
- BFAKENXZKHGIGE-UHFFFAOYSA-N bis(2,3,5,6-tetrafluoro-4-iodophenyl)diazene Chemical compound FC1=C(C(=C(C(=C1F)I)F)F)N=NC1=C(C(=C(C(=C1F)F)I)F)F BFAKENXZKHGIGE-UHFFFAOYSA-N 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 101150011432 apy gene Proteins 0.000 description 2
- 101150011633 crtI gene Proteins 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 201000007795 Bietti crystalline corneoretinal dystrophy Diseases 0.000 description 1
- 208000008319 Bietti crystalline dystrophy Diseases 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 229960003161 interferon beta-1b Drugs 0.000 description 1
- 229960001267 nesiritide Drugs 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940005267 urate oxidase Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762515870P | 2017-06-06 | 2017-06-06 | |
| US62/515,870 | 2017-06-06 | ||
| PCT/US2018/036333 WO2018226880A1 (en) | 2017-06-06 | 2018-06-06 | A htp genomic engineering platform for improving escherichia coli |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020524490A JP2020524490A (ja) | 2020-08-20 |
| JP2020524490A5 true JP2020524490A5 (enExample) | 2021-07-26 |
Family
ID=62751581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567283A Pending JP2020524490A (ja) | 2017-06-06 | 2018-06-06 | Ｅｓｃｈｅｒｉｃｈｉａ Ｃｏｌｉを改良するためのＨＴＰゲノム操作プラットフォーム |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200370058A1 (enExample) |
| EP (2) | EP3878961A1 (enExample) |
| JP (1) | JP2020524490A (enExample) |
| KR (1) | KR20200026874A (enExample) |
| CN (1) | CN110945125A (enExample) |
| CA (1) | CA3064612A1 (enExample) |
| ES (1) | ES2875579T3 (enExample) |
| WO (1) | WO2018226880A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019103020A1 (ja) * | 2017-11-22 | 2019-05-31 | 国立大学法人神戸大学 | 安定で副作用の少ないゲノム編集用複合体及びそれをコードする核酸 |
| WO2020092704A1 (en) | 2018-10-31 | 2020-05-07 | Zymergen Inc. | Multiplexed deterministic assembly of dna libraries |
| JP2022524043A (ja) * | 2019-03-08 | 2022-04-27 | ザイマージェン インコーポレイテッド | 微生物の反復ゲノム編集 |
| US11053515B2 (en) | 2019-03-08 | 2021-07-06 | Zymergen Inc. | Pooled genome editing in microbes |
| US11526705B2 (en) * | 2019-04-01 | 2022-12-13 | Lg Electronics Inc. | Method of classificating outlier in object recognition and device and robot of classifying thereof |
| WO2020255054A1 (en) * | 2019-06-21 | 2020-12-24 | Glycom A/S | Nucleic acid construct comprising 5' utr stem-loop for in vitro and in vivo gene expression |
| CN110272907B (zh) * | 2019-08-12 | 2021-04-23 | 华中农业大学 | 一种调控番茄茎杆发育的基因sd1及其应用 |
| GB202001211D0 (en) * | 2020-01-29 | 2020-03-11 | Imperial College Innovations Ltd | Methods |
| CN111612133B (zh) * | 2020-05-20 | 2021-10-19 | 广州华见智能科技有限公司 | 基于人脸图像多阶段关系学习的内脏器官特征编码方法 |
| CN111700075B (zh) * | 2020-06-05 | 2021-08-17 | 茂名市瑜丰沉香创意产业有限公司 | 人工结香沉香、沉香精油富集液、沉香香皂及其生产方法 |
| WO2022124302A1 (ja) * | 2020-12-08 | 2022-06-16 | 国立大学法人神戸大学 | 有用化合物を高生産する代謝改変微生物株の構築方法及び代謝改変大腸菌株 |
| CN112941058B (zh) * | 2021-04-02 | 2023-12-05 | 重庆科润生物医药研发有限公司 | 一种重组溶组织梭菌ii型胶原酶及其制备方法和应用 |
| CN113265412A (zh) * | 2021-05-20 | 2021-08-17 | 北京化工大学 | 多酶偶联定位体系及其构建方法和应用 |
| CN113393900B (zh) * | 2021-06-09 | 2022-08-02 | 吉林大学 | 基于改进Transformer模型的RNA状态推断研究方法 |
| US11530406B1 (en) | 2021-08-30 | 2022-12-20 | Sachi Bioworks Inc. | System and method for producing a therapeutic oligomer |
| US12037621B2 (en) * | 2021-09-15 | 2024-07-16 | Archer-Daniels-Midland Company | Threonine production strain having attenuated expression of the yafV gene |
| CN114672505A (zh) * | 2022-03-15 | 2022-06-28 | 江苏省中国科学院植物研究所 | 一种功能性表达细胞色素p450酶的方法及其应用 |
| CN114921463B (zh) * | 2022-04-11 | 2023-12-01 | 中国农业科学院生物技术研究所 | 一种调控萜类化合物合成产量的人工非编码RNA分子CsiY及其应用 |
| CN115074410B (zh) * | 2022-06-30 | 2025-08-19 | 武汉合生科技有限公司 | 一种生物合成虾青素的方法及载体 |
| CN115992160A (zh) * | 2022-09-30 | 2023-04-21 | 倍生生物科技(深圳)有限公司 | 一种穿梭载体及其构建方法和应用 |
| CN115820703A (zh) * | 2022-12-20 | 2023-03-21 | 山东乾肽生物科技有限公司 | 利用rna环化技术制备寡肽的方法及寡肽的表达dna |
| CN116013407B (zh) * | 2022-12-26 | 2025-06-27 | 杭州智科慧创科技有限公司 | 一种基于语言模型的性质解耦蛋白质生成方法 |
| CN116504313A (zh) * | 2023-05-08 | 2023-07-28 | 暨南大学 | 基因终止子查询方法、装置、设备及可读存储介质 |
| CN117275590B (zh) * | 2023-11-10 | 2024-03-26 | 华东师范大学 | 有机固废体系中大分子的降解功能基因数据库与分析平台 |
| KR20250069469A (ko) * | 2023-11-10 | 2025-05-19 | 한국과학기술원 | TdT(Terminal deoxynucleotidyl transferase) 및 dNTP를 이용한 비번역영역 (untranslated region) 라이브러리 합성 방법 |
| CN117238380A (zh) * | 2023-11-15 | 2023-12-15 | 中国医学科学院北京协和医院 | 宏基因组病原识别的ai推荐方法、装置、设备及介质 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US824A (en) | 1838-07-09 | Construction of steam-engines | ||
| US72197A (en) | 1867-12-17 | Jesse h | ||
| US4435504A (en) | 1982-07-15 | 1984-03-06 | Syva Company | Immunochromatographic assay with support having bound "MIP" and second enzyme |
| GB8406752D0 (en) | 1984-03-15 | 1984-04-18 | Unilever Plc | Chemical and clinical tests |
| CA1303983C (en) | 1987-03-27 | 1992-06-23 | Robert W. Rosenstein | Solid phase assay |
| US4855240A (en) | 1987-05-13 | 1989-08-08 | Becton Dickinson And Company | Solid phase assay employing capillary flow |
| US6060296A (en) | 1991-07-03 | 2000-05-09 | The Salk Institute For Biological Studies | Protein kinases |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5837458A (en) * | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6117679A (en) * | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6090592A (en) | 1994-08-03 | 2000-07-18 | Mosaic Technologies, Inc. | Method for performing amplification of nucleic acid on supports |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| EP1007732B1 (en) * | 1997-01-17 | 2006-07-26 | Maxygen, Inc. | EVOLUTION OF procaryotic WHOLE CELLS BY RECURSIVE SEQUENCE RECOMBINATION |
| US6326204B1 (en) * | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| ATE364718T1 (de) | 1997-04-01 | 2007-07-15 | Solexa Ltd | Verfahren zur vervielfältigung von nukleinsäure |
| JPH1180185A (ja) | 1997-09-05 | 1999-03-26 | Res Dev Corp Of Japan | オリゴヌクレオチドの化学合成法 |
| US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
| CA2321088A1 (en) | 1998-02-20 | 1999-08-26 | Genome Dynamics, Inc. | Method for designing dna-binding proteins of the zinc-finger class |
| AR021833A1 (es) | 1998-09-30 | 2002-08-07 | Applied Research Systems | Metodos de amplificacion y secuenciacion de acido nucleico |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6300070B1 (en) | 1999-06-04 | 2001-10-09 | Mosaic Technologies, Inc. | Solid phase methods for amplifying multiple nucleic acids |
| US6927046B1 (en) * | 1999-12-30 | 2005-08-09 | Archer-Daniels-Midland Company | Increased lysine production by gene amplification using coryneform bacteria |
| US7785832B2 (en) * | 2000-05-09 | 2010-08-31 | HALLA Patent & Law Firm | Method of protein synthesis |
| WO2002029032A2 (en) * | 2000-09-30 | 2002-04-11 | Diversa Corporation | Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating |
| JP2004537260A (ja) | 2000-12-07 | 2004-12-16 | サンガモ バイオサイエンシーズ， インコーポレイテッド | ジンクフィンガータンパク質による血管新生の調節 |
| US7067617B2 (en) | 2001-02-21 | 2006-06-27 | The Scripps Research Institute | Zinc finger binding domains for nucleotide sequence ANN |
| US20070178454A1 (en) | 2002-10-21 | 2007-08-02 | Joung J K | Context sensitive paralell optimization of zinc finger dna binding domains |
| WO2005021772A1 (en) | 2003-08-29 | 2005-03-10 | Degussa Ag | Process for the preparation of l-lysine |
| JP2009538622A (ja) | 2006-05-30 | 2009-11-12 | ダウ グローバル テクノロジーズ インコーポレイティド | コドン最適化法 |
| CN101177454B (zh) * | 2007-05-09 | 2010-09-22 | 郑骏年 | Il-18突变体多肽及制备及用途 |
| EP2255005A4 (en) | 2008-02-28 | 2012-01-25 | Univ California | USE OF SYNTHETIC EQUIPMENT FOR THE PRODUCTION OF BIOSYNTHESIS PATH PRODUCTS |
| EP2313507A2 (en) * | 2008-07-03 | 2011-04-27 | Pfenex Inc | High throughput screening method and use thereof to identify a production platform for a multifunctional binding protein |
| US8808986B2 (en) | 2008-08-27 | 2014-08-19 | Gen9, Inc. | Methods and devices for high fidelity polynucleotide synthesis |
| US20100137143A1 (en) | 2008-10-22 | 2010-06-03 | Ion Torrent Systems Incorporated | Methods and apparatus for measuring analytes |
| US8783382B2 (en) | 2009-01-15 | 2014-07-22 | Schlumberger Technology Corporation | Directional drilling control devices and methods |
| WO2010094772A1 (en) | 2009-02-20 | 2010-08-26 | Febit Holding Gmbh | Synthesis of sequence-verified nucleic acids |
| US8574835B2 (en) | 2009-05-29 | 2013-11-05 | Life Technologies Corporation | Scaffolded nucleic acid polymer particles and methods of making and using |
| EP2395087A1 (en) | 2010-06-11 | 2011-12-14 | Icon Genetics GmbH | System and method of modular cloning |
| KR101335841B1 (ko) * | 2010-12-21 | 2013-12-02 | 씨제이제일제당 (주) | 호모세린 아세틸 트랜스퍼라제 활성을 가지는 변이형 폴리펩티드 및 이를 발현하는 미생물 |
| US20150368639A1 (en) * | 2011-04-14 | 2015-12-24 | Ryan T. Gill | Compositions, methods and uses for multiplex protein sequence activity relationship mapping |
| JP6158170B2 (ja) * | 2011-04-27 | 2017-07-12 | アミリス， インコーポレイテッド | ゲノム修飾のための方法 |
| CN102352337B (zh) * | 2011-08-03 | 2014-04-23 | 中国人民解放军军事医学科学院生物工程研究所 | 利用异源启动子控制大肠杆菌基因组n-乙酰基转移酶表达重组菌及应用 |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| SI3401400T1 (sl) | 2012-05-25 | 2019-10-30 | Univ California | Postopki in sestavki za RNA usmerjeno modifikacijo tarčne DNA in za RNA usmerjeno modulacijo prepisovanja |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| EP2931898B1 (en) | 2012-12-12 | 2016-03-09 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| CN105658796B (zh) | 2012-12-12 | 2021-10-26 | 布罗德研究所有限公司 | 用于序列操纵的crispr-cas组分系统、方法以及组合物 |
| CN113355357B (zh) | 2012-12-12 | 2024-12-03 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| ES2536353T3 (es) | 2012-12-12 | 2015-05-22 | The Broad Institute, Inc. | Ingeniería de sistemas, métodos y composiciones de guía optimizadas para manipulación de secuencias |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| DK3553174T3 (da) | 2012-12-17 | 2025-08-04 | Harvard College | Rna-guided modificering af humant genom |
| CA2930015A1 (en) | 2013-11-07 | 2015-05-14 | Editas Medicine, Inc. | Crispr-related methods and compositions with governing grnas |
| DK3215618T3 (da) | 2014-11-05 | 2019-10-14 | Illumina Inc | Transposasesammensætninger til reduktion af insertionsbias |
| SG10201804715WA (en) | 2015-01-28 | 2018-07-30 | Pioneer Hi Bred Int | Crispr hybrid dna/rna polynucleotides and methods of use |
| US9738687B2 (en) | 2015-04-10 | 2017-08-22 | Feldan Bio Inc. | Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| KR102356072B1 (ko) | 2015-09-10 | 2022-01-27 | 에스케이하이닉스 주식회사 | 메모리 시스템 및 그 동작 방법 |
| US9677090B2 (en) | 2015-10-23 | 2017-06-13 | Caribou Biosciences, Inc. | Engineered nucleic-acid targeting nucleic acids |
| US9988624B2 (en) * | 2015-12-07 | 2018-06-05 | Zymergen Inc. | Microbial strain improvement by a HTP genomic engineering platform |
| US11151497B2 (en) * | 2016-04-27 | 2021-10-19 | Zymergen Inc. | Microbial strain design system and methods for improved large-scale production of engineered nucleotide sequences |
| KR20180084756A (ko) * | 2015-12-07 | 2018-07-25 | 지머젠 인코포레이티드 | 코리네박테리움 글루타미컴으로부터의 프로모터 |
| CA3105722C (en) * | 2015-12-07 | 2022-10-11 | Zymergen Inc. | Microbial strain improvement by a htp genomic engineering platform |
| US9896696B2 (en) | 2016-02-15 | 2018-02-20 | Benson Hill Biosystems, Inc. | Compositions and methods for modifying genomes |
-
2018
- 2018-06-06 EP EP21162339.2A patent/EP3878961A1/en not_active Withdrawn
- 2018-06-06 ES ES18734715T patent/ES2875579T3/es active Active
- 2018-06-06 WO PCT/US2018/036333 patent/WO2018226880A1/en not_active Ceased
- 2018-06-06 EP EP18734715.8A patent/EP3485013B1/en active Active
- 2018-06-06 US US16/620,069 patent/US20200370058A1/en not_active Abandoned
- 2018-06-06 JP JP2019567283A patent/JP2020524490A/ja active Pending
- 2018-06-06 CN CN201880047657.XA patent/CN110945125A/zh active Pending
- 2018-06-06 KR KR1020207000237A patent/KR20200026874A/ko not_active Withdrawn
- 2018-06-06 CA CA3064612A patent/CA3064612A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524490A5 (enExample) | ||
| Coco et al. | Growth factor engineering by degenerate homoduplex gene family recombination | |
| AU2012340175B2 (en) | Systems and methods for engineering nucleic acid constructs using scoring techniques | |
| AU2007287327B2 (en) | Matrix attachment regions (MARs) for increasing transcription and uses thereof | |
| CN109136248B (zh) | 多靶点编辑载体及其构建方法和应用 | |
| JP2020524493A5 (enExample) | ||
| Van Tol et al. | Artificial transcription factor-mediated regulation of gene expression | |
| WO2008076368A2 (en) | Fragment-rearranged nucleic acids and uses thereof | |
| EP2921560B1 (en) | Method for synthesizing gene library using codon combination and mutagenesis | |
| US20160017410A1 (en) | Highly multiplex single amino acid mutagenesis for massively parallel functional analysis | |
| CN111971389A (zh) | CRISPR/Cas系统在基因编辑中的应用 | |
| Pohlschroder et al. | Haloferax volcanii: a versatile model for studying archaeal biology | |
| US20110097709A1 (en) | Method for modifying a nucleic acid | |
| EP3363900A1 (en) | Evolution-guided multiplexed dna assembly of dna parts, pathways and genomes | |
| WO2018066492A1 (ja) | Ｈｓｐａ５遺伝子のプロモーター | |
| CN101541959A (zh) | 用于增加转录的基质附着区（mar）及其应用 | |
| CN116200366A (zh) | 具有XNA合成及反转录活性的Bst DNA聚合酶突变株 | |
| CN104404069B (zh) | 一种低拷贝pTerm质粒及其构建方法和应用 | |
| WO2006047669A2 (en) | Non-random method of gene shuffling | |
| CN109477134A (zh) | 转座酶竞争物控制系统 | |
| CN115052980B (zh) | 衍生自黄杆菌的基因编辑系统 | |
| Huang et al. | Characterization of the macronuclear and micronuclear pheromone genes of Euplotes raikovi reveals the origin of the mating type genetic diversity | |
| Li et al. | Enrichment of prime-edited mammalian cells with surrogate PuroR reporters | |
| KR20240095313A (ko) | Cas 단백질 또는 이의 변이체의 스크리닝 방법, 및 이를 이용하여 제조된 Cas 단백질 또는 이의 변이체 | |
| Ebner et al. | Exploiting Self-Processing 2A Peptides for Multigene Expression in Pichia pastoris |